Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 569

1.

Potential new drug targets for osteoporosis.

Deal C.

Nat Clin Pract Rheumatol. 2009 Jan;5(1):20-7. doi: 10.1038/ncprheum0977. Review. Erratum in: Nat Clin Pract Rheumatol. 2009 Mar;5(3):174.

PMID:
19098925
2.

Future therapeutic targets in osteoporosis.

Deal C.

Curr Opin Rheumatol. 2009 Jul;21(4):380-5. doi: 10.1097/BOR.0b013e32832cbc2a. Review.

PMID:
19461517
3.

Emerging anabolic treatments in osteoporosis.

Mosekilde L, Tørring O, Rejnmark L.

Curr Drug Saf. 2011 Apr;6(2):62-74. Review.

PMID:
21524248
4.

New therapeutic targets for osteoporosis: beyond denosumab.

Lim V, Clarke BL.

Maturitas. 2012 Nov;73(3):269-72. doi: 10.1016/j.maturitas.2012.08.002. Epub 2012 Aug 24. Review.

PMID:
22925430
5.

The future of osteoporosis treatment - a research update.

Lippuner K.

Swiss Med Wkly. 2012 Jul 19;142:w13624. doi: 10.4414/smw.2012.13624. Review.

6.

Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.

Bilezikian JP, Rubin MR.

Curr Osteoporos Rep. 2006 Mar;4(1):5-13. Review.

PMID:
16527002
7.

Emerging pharmacologic therapies for osteoporosis.

Grey A.

Expert Opin Emerg Drugs. 2007 Sep;12(3):493-508. Review.

PMID:
17874975
8.

Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.

Bilezikian JP.

Curr Osteoporos Rep. 2008 Mar;6(1):24-30. Review.

PMID:
18430397
9.

Investigational anabolic therapies for osteoporosis.

Trivedi R, Goswami R, Chattopadhyay N.

Expert Opin Investig Drugs. 2010 Aug;19(8):995-1005. doi: 10.1517/13543784.2010.501077. Review.

PMID:
20629616
10.

Future developments in osteoporosis therapy.

Ng KW.

Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):371-84.

PMID:
19857200
11.

The use of parathyroid hormone in the treatment of osteoporosis.

Girotra M, Rubin MR, Bilezikian JP.

Rev Endocr Metab Disord. 2006 Jun;7(1-2):113-21. Review.

PMID:
17043762
12.

Parathyroid hormone as an anabolic skeletal therapy.

Rubin MR, Bilezikian JP.

Drugs. 2005;65(17):2481-98. Review.

PMID:
16296873
13.

Wnt signalling pathway: a new target for the treatment of osteoporosis.

Rawadi G, Roman-Roman S.

Expert Opin Ther Targets. 2005 Oct;9(5):1063-77. Review.

PMID:
16185158
14.

Biological agents in management of osteoporosis.

Tella SH, Gallagher JC.

Eur J Clin Pharmacol. 2014 Nov;70(11):1291-301. doi: 10.1007/s00228-014-1735-5. Epub 2014 Sep 11. Review.

PMID:
25204309
15.

Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Martin TJ, Sims NA, Ng KW.

Osteoporos Int. 2008 Aug;19(8):1125-38. doi: 10.1007/s00198-008-0575-5. Epub 2008 Mar 13. Review.

PMID:
18338097
16.

New treatment targets in osteoporosis.

Roux S.

Joint Bone Spine. 2010 May;77(3):222-8. doi: 10.1016/j.jbspin.2010.02.004. Epub 2010 Apr 8. Review.

PMID:
20381400
17.

Osteoporosis: now and the future.

Rachner TD, Khosla S, Hofbauer LC.

Lancet. 2011 Apr 9;377(9773):1276-87. doi: 10.1016/S0140-6736(10)62349-5. Epub 2011 Mar 28. Review.

18.

Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis.

Whitfield JF, Morley P, Willick GE.

Treat Endocrinol. 2002;1(3):175-90. Review.

PMID:
15799210
19.

Anabolic therapy for osteoporosis: parathyroid hormone.

Cosman F.

Curr Osteoporos Rep. 2005 Dec;3(4):143-9. Review.

PMID:
16303114
20.

[Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].

Quemerais-Durieu MA, Kerlan V, Chabre O.

Ann Endocrinol (Paris). 2011 Oct;72 Suppl 1:S15-22. doi: 10.1016/S0003-4266(11)70005-1. French.

PMID:
22008272
Items per page

Supplemental Content

Write to the Help Desk